Norges Bank Kinnate Biopharma Inc. Call Options Transaction History
Norges Bank
- $716 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KNTE
# of Institutions
2Shares Held
292KCall Options Held
0Put Options Held
0About Kinnate Biopharma Inc.
- Ticker KNTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,145,600
- Description
- Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...